Valneva IPO Presentation Deck

VLA1553: Clinical Data in Phase 1 in 120 Subjects Clinical Trial VLA1553-101 Published in Lancet ID¹ Immunogenicity 100% Seroconversion Rate achieved at Day 14 after a single vaccination in all dose groups; fully sustained at 100% by Month 12 A single vaccination of VLA1553 was sufficient to induce sustaining, high-titer, neutralizing antibodies at all dose levels one year after priming ■Upon Re-Vaccination ("Challenge"): No anamnestic response No vaccine-strain viremia Highly immunogenic after single vaccination 1 Wressnigg et al. 2020; Lancet Infect Dis 20:1193-1203. Valneva - Roadshow Presentation V Safety No safety concerns identified, well- tolerated in the low and medium doses Excellent local tolerability ■ Systemic adverse events included short- term fever, headache and fatigue, muscle pain No vaccine related Serious Adverse Events or Adverse Events of Special Interest Safety profile supported Phase 3 progression with medium dose April 2021 22

View entire presentation